Trump Announces All 50 States Joining Medicaid Drug Pricing Model Aimed at Lowering Costs

President Donald Trump announced Friday that all 50 states will participate in a newly introduced program aimed at bringing Most Favored Nation pricing to select medications within the Medicaid program. According to the Trump administration, the initiative—dubbed the Medicaid "GENEROUS" model—will lower the net price of selected prescription drugs down to levels paid in certain other affluent nations, potentially saving billions of dollars.

Speaking to reporters in the Oval Office on Friday, Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare & Medicaid Services Administrator Mehmet Oz. During the announcement, Trump emphasized the political and financial significance of the program, stating that the initiative alone should influence upcoming political outcomes.

The announcement arrives as cost-of-living concerns take center stage for voters ahead of the November midterm elections. To address pharmaceutical affordability, the administration has pursued agreements with drug companies to ensure U.S. prescription prices align more closely with international rates. However, critics note that broader health care costs remain a prominent concern, particularly after congressional Republicans allowed Affordable Care Act subsidies to expire earlier in the year, which drove up plan costs for many consumers.

The underlying policy traces back to an executive order signed by Trump last year, establishing a Most Favored Nations policy intended to commit the U.S. to paying the lowest price found internationally for medications. Earlier in May, White House projections estimated that these pharmaceutical agreements could generate roughly $529 billion in savings over a decade.

Medicaid is a joint state and federal program providing coverage for individuals with low incomes. While patients enrolled in Medicaid typically pay only a nominal co-payment of a few dollars to fill prescriptions, reduced drug acquisition costs could relieve financial pressure on state budgets that help fund the health care programs. Trump noted that participating states will have the flexibility to utilize the projected billions in savings toward alternative health care improvements or other priorities.

Despite the administration's optimistic projections, independent verification of the financial impact remains challenging. Few specifics regarding the agreements struck between the administration and participating pharmaceutical companies have been released to the public.

White House spokesman Kush Desai defended the confidentiality of the terms, drawing a parallel to drug negotiations conducted during former President Joe Biden's administration under the Inflation Reduction Act, which also withheld commercially sensitive information. Desai contended that critics questioning the non-disclosure of Trump's drug deals should be viewed cautiously.

Meanwhile, health policy experts emphasize the need for greater transparency. Kathy Hempstead, a senior policy adviser at the Robert Wood Johnson Foundation, told The Associated Press that the lack of granular data creates hurdles for lawmakers who are being urged by the administration to codify the Most Favored Nation arrangements into law. Hempstead also raised questions regarding the long-term durability of the price reductions, noting uncertainty over whether costs might rise again once the current administration leaves office.

Other stakeholders have called for broader relief across the health care landscape. JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, remarked that while Friday's announcement represents notable headway, the reform remains incomplete because millions of Americans outside government-subsidized programs continue seeking lower drug prices.

Prescription drug expenses in the United States are influenced by various market dynamics, including product competition and specific insurance coverage terms. The majority of Americans obtain coverage through employer-sponsored plans, the individual insurance market, or public programs like Medicare and Medicaid, which mitigate direct exposure to steep retail drug prices.